 (Gut 1995; 36: 935-938) 
has been shown to be of benefit in the treatment of this disease and is virtually free of side effects. 2 UDCA was proposed as a therapeutic approach to PBC on the basis that endogenous hydrophobic bile acids accumulate in chronic cholestatic disease and can result in hepatocyte damage.2 This theory is controversial, however, as several authors have described a change to a more hydrophilic acid composition in cholestatic liver disease.3 UDCA administration increases the concentrations of hydrophilic bile acids and prevents the hepatotoxic effects of other bile acids.4 5 In addition, it has recently been found to reduce HIA antigen expression on bile duct cells and hepatocytes.6 Biochemical improvements seen in patients treated with UDCA may be the result of these effects. In controlled and uncontrolled clinical trials, UDCA has been shown to improve biochemical tests of liver function and in two of the studies, improvement of liver histology was noted.7-9 In addition, the lack of associated major toxicity makes it the current treatment of choice among many physicians for patients with PBC.
During 1988 we began a randomised, double blind trial evaluating UDCA in the treatment of PBC in which we concluded that UDCA is an effective therapy for patients with PBC. UDCA was associated with delayed progression of the disease and lack of side effects. As part of our analysis a subset of patients was found who completely normalised their liver biochemical functions during two years of treatment. This finding led us to further evaluate the characteristics that distinguished these patients from those with a less complete biochemical response.
Methods
The patients described were enrolled in a randomised, double blind controlled trial designed to evaluate UDCA in the treatment of PBC. One hundred and eighty patients were entered with 89 patients randomised to receive UDCA and 91 to receive placebo. Sixty five of the patients treated with UDCA and 53 of the placebo treated patients had at least two years of follow up. All patients met criteria for the diagnosis of PBC including chronic cholestatic liver disease of at least six months' duration, an increase in alkaline phosphatase activity of at least 1. 5 Patients were assigned to receive either UDCA or placebo. The treatment was given with meals and a bedtime snack three to four times per day, depending on the patient's weight, administering the 250 mg tablets in a daily dose of 13-15 mg/kg/day. Patients, nurses, and physicians were blinded as to whether the patient was assigned to UDCA or placebo.
Statistics
Data were entered and stored using the Clinfo software package. Student's t test was used for normally distributed paired samples and the Wilcoxon rank sum was used for nonparametric data.
Results
Of the 65 patients receiving UDCA who had two years of follow up, 12 A total of 19 patients (7 receiving UDCA, 12 receiving placebo) died or were transplanted within the two year follow up period. When entry characteristics of these patients were compared with the 12 patients who normalised their biochemical functions, differences were noted in liver functions and histological stage. The patients who died or were transplanted presented with significantly higher values of alkaline phosphatase, AST, and total serum bilirubin. They were also histologically more advanced (Table I) .
Changes over the initial three months from baseline alkaline phosphatase activities were compared between the group of 12 patients who normalised their liver function tests while receiving UDCA, the 7 patients who died or required a transplant while receiving UDCA, and the placebo treated patients. In the group of 12 patients there was a reduction in alkaline phosphatase activities of 84% towards the upper limit of normal (250 U/1). This compared with a reduction of 56% in the UDCA treated patients who died or required a transplant (p =0.004), and an increase of 13% in the placebo treated patients (p=0.0001).
At represented a group with less severe disease although they overall were histologically similar. Values of alkaline phosphatase and total serum bilirubin were significantly lower in these patients at entry. Biochemical normalisation at two years could not be predicted from the response at three months. The percentage of UDCA in biliary bile was significantly higher in these patients after two years of treatment. It is possible that the increased concentrations of UDCA in bile are directly related to the improved response seen in this group of patients. Because all patients received the drug in a dose of 13 to 15 mg/kg/day some patients may have better absorption or compliance, or both with the dose regimen. Efforts to further improve enrichment of bile with UDCA particularly in those patients who exhibited a less complete response should be assessed. Such approaches may entail increased doses of UDCA to increase bile acid enrichment or addition of other drugs to inhibit production of endogenous bile acid given along with UDCA.13 14 When the clinical course of these patients was compared with the patients who did not normalise their liver functions we found no differences with respect to changes in symptoms (pruritus or fatigue), histological progression, development of varices or ascites or progression to death or transplant. Longer follow up in more patients would be required to detect significant differences in these criteria, however.
We did find that 1 1 of 12 patients who normalised (92%) either remained stable histologically or improved compared with 72% in the group who did not normalise. Three of the patients with normal liver tests who improved histologically returned to stage 1 and in two of these patients diagnostic abnormalities suggestive of PBC were not found at two years. None of the patients in the group who did not normalise returned to stage 1. It would seem that there may be a trend toward corresponding histological improvement or remission in the patients who normalise although again longer follow up is probably required. Histological improvement has been suggested in other trials with UDCA. Leuschner et al7 showed improvement in hepatic histology in six of 10 patients receiving UDCA compared with only one of eight placebo patients. Poupon showed improvement in parameters of inflammation on liver biopsy in patients receiving UDCA compared with those receiving placebo at two years.2
The patients who normalised presented with lower initial concentrations of serum bilirubin, which would predict a better prognosis as bilirubin has been shown to be the most J7orgensen, Dickson, 
